{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalComment":"on the van der Waerden normal scores","statisticalMethod":"ANOVA","testedNonInferiority":false},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalComment":"on the van der Waerden normal scores","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.61","value":"129.6"},{"groupId":"OG001","spread":"33.93","value":"131.7"},{"groupId":"OG002","spread":"33.90","value":"127.2"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.25","value":"14.8"},{"groupId":"OG001","spread":"33.72","value":"27.0"},{"groupId":"OG002","spread":"34.28","value":"26.9"}]}],"title":"Change at Week 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"252"},{"groupId":"OG002","value":"255"}],"units":"Participants"}],"description":"The IBDQ is used to measure disease specific quality of life on a 32 Likert-scaled items questionnaire. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function and social function with scores ranging from 10 to 70, 5 to 35, 12 to 84 and 5 to 35 respectively and the total score ranges from 32 to 224. Higher scores indicate better health related quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo subcutaneous injection (given under the skin by way of a needle) matched to golimumab administered at Week 0 and Week 2.","id":"OG000","title":"Placebo"},{"description":"Golimumab 200 mg subcutaneous injection was administered at Week 0 and dose was decreased to 100 mg at Week 2.","id":"OG001","title":"Golimumab 200 mg -> 100 mg"},{"description":"Golimumab 400 mg subcutaneous injection was administered at Week 0 and dose was decreased to 200 mg at Week 2.","id":"OG002","title":"Golimumab 400 mg -> 200 mg"}],"paramType":"MEAN","populationDescription":"Efficacy analysis population included all the participants who were randomly assigned to the study after the dose selection. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 6","title":"Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 6","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}